Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Medpace (MEDP) Share Price

News headlines about Medpace (NASDAQ:MEDP) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medpace earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.581821843049 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

MEDP has been the subject of a number of research reports. Zacks Investment Research cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. BidaskClub cut shares of Medpace from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. William Blair cut shares of Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Jefferies Group boosted their target price on shares of Medpace from $34.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Finally, Robert W. Baird boosted their target price on shares of Medpace from $32.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 31st. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $36.60.

Shares of Medpace (MEDP) opened at $37.53 on Wednesday. Medpace has a one year low of $21.76 and a one year high of $39.64. The stock has a market cap of $1,375.46, a PE ratio of 55.19, a P/E/G ratio of 1.56 and a beta of -0.76. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68.

In related news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 25.80% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Medpace (MEDP) Share Price” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-medpace-medp-share-price.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply